Victor Perez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5184055/publications.pdf

Version: 2024-02-01

71685 50276 7,142 181 46 76 citations h-index g-index papers 197 197 197 8646 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Mapping the neural systems driving breathing at the transition to unconsciousness. Neurolmage, 2022, 246, 118779.	4.2	3
2	Multidimensional predictors of negative symptoms in antipsychotic-naive first-episode psychosis. Journal of Psychiatry and Neuroscience, 2022, 47, E21-E31.	2.4	5
3	Real-world Implementation of a Smartphone-Based Psychoeducation Program for Bipolar Disorder: Observational Ecological Study. Journal of Medical Internet Research, 2022, 24, e31565.	4.3	6
4	Psychological impact of the COVID-19 pandemic on primary care workers: a cross-sectional study. British Journal of General Practice, 2022, 72, e501-e510.	1.4	17
5	Cognitive and qualityâ€ofâ€life related factors of body mass index (BMI) improvement after deep brain stimulation in the subcallosal cingulate and nucleus accumbens in treatmentâ€refractory chronic anorexia nervosa. European Eating Disorders Review, 2022, , .	4.1	2
6	Brain activity and connectivity differences in reward value discrimination during effort computation in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 647-659.	3.2	3
7	Olfactory Neuroepithelium Cells from Cannabis Users Display Alterations to the Cytoskeleton and to Markers of Adhesion, Proliferation and Apoptosis. Molecular Neurobiology, 2021, 58, 1695-1710.	4.0	6
8	A multicenter, observational study of pain and functional impairment in individuals with major depressive disorder in partial remission: the DESIRE study. Journal of Affective Disorders, 2021, 281, 657-660.	4.1	2
9	Mental health impact of the first wave of COVID-19 pandemic on Spanish healthcare workers: A large cross-sectional survey. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 90-105.	1.8	133
10	The Prevalence and Clinical and Sociodemographic Factors of Problem Online Gambling: A Systematic Review. Journal of Gambling Studies, 2021, 37, 899-926.	1.6	23
11	The impact of the Catalonia Suicide Risk Code (CSRC) in a tertiary hospital: Reduction in hospitalizations and emergency room visits for any reason but not for suicide attempt. Revista De PsiquiatrÃa Y Salud Mental, 2021, , .	1.8	1
12	Differences between the child and adult brain in the local functional structure of the cerebral cortex. Neurolmage, 2021, 237, 118150.	4.2	7
13	Is the COVID-19 pandemic a risk factor for suicide attempts in adolescent girls?. Journal of Affective Disorders, 2021, 292, 139-141.	4.1	65
14	Epidemiology and costs of depressive disorder in Spain: the EPICO study. European Neuropsychopharmacology, 2021, 50, 93-103.	0.7	28
15	Thirtyâ€day suicidal thoughts and behaviors among hospital workers during the first wave of the Spain COVIDâ€19 outbreak. Depression and Anxiety, 2021, 38, 528-544.	4.1	70
16	Determinants of mechanical restraint in an acute psychiatric care unit. World Journal of Psychiatry, 2021, 11, 854-863.	2.7	5
17	Self-reported Subjective Effects of Analytically Confirmed New Psychoactive Substances Consumed by e-Psychonauts: Protocol for a Longitudinal Study Using a New Internet-Based Methodology. JMIR Research Protocols, 2021, 10, e24433.	1.0	3
18	Mindfulness-Based Cognitive Therapy Delivered in Primary Care: a Naturalistic, Mixed-Methods Study of Participant Characteristics and Experiences. Mindfulness, 2020, 11, 291-302.	2.8	6

#	Article	IF	CITATIONS
19	Deep brain stimulation in treatment resistant schizophrenia: A pilot randomized cross-over clinical trial. EBioMedicine, 2020, 51, 102568.	6.1	50
20	Suicide. The post-COVID era: A time for action. Revista De PsiquiatrÃa Y Salud Mental, 2020, 13, 229-231.	1.8	1
21	The Suicide Prevention and Intervention Study (SURVIVE): Study protocol for a multisite cohort study with nested randomized-controlled trials. Revista De PsiquiatrÃa Y Salud Mental, 2020, , .	1.8	1
22	Optimizing Behavioral Paradigms to Facilitate Development of New Treatments for Anhedonia and Reward Processing Deficits in Schizophrenia and Major Depressive Disorder: Study Protocol. Frontiers in Psychiatry, 2020, 11, 536112.	2.6	3
23	Traumatic Events in Dual Disorders: Prevalence and Clinical Characteristics. Journal of Clinical Medicine, 2020, 9, 2553.	2.4	8
24	Brain metabolic changes in patients with treatment resistant schizophrenia treated with deep brain stimulation: A series of cases. Journal of Psychiatric Research, 2020, 127, 57-61.	3.1	8
25	What ketamine can teach us about the opioid system in depression?. Expert Opinion on Drug Discovery, 2020, 15, 1369-1372.	5.0	5
26	The Catalonia Suicide Risk Code: A secondary prevention program for individuals at risk of suicide. Journal of Affective Disorders, 2020, 268, 201-205.	4.1	20
27	Family Features of Social Withdrawal Syndrome (Hikikomori). Frontiers in Psychiatry, 2020, 11, 138.	2.6	25
28	A Multicenter Phase II RCT to Compare the Effectiveness of EMDR Versus TAU in Patients With a First-Episode Psychosis and Psychological Trauma: A Protocol Design. Frontiers in Psychiatry, 2020, 10, 1023.	2.6	5
29	A Randomized Trial of Deep Brain Stimulation to the Subcallosal Cingulate and Nucleus Accumbens in Patients with Treatment-Refractory, Chronic, and Severe Anorexia Nervosa: Initial Results at 6 Months of Follow Up. Journal of Clinical Medicine, 2020, 9, 1946.	2.4	23
30	Effects of Cannabis Use on the Protein and Lipid Profile of Olfactory Neuroepithelium Cells from Schizophrenia Patients Studied by Synchrotron-Based FTIR Spectroscopy. Biomolecules, 2020, 10, 329.	4.0	5
31	A prospective longitudinal study searching for predictors of response to group psychoeducation in bipolar disorder. Journal of Affective Disorders, 2020, 274, 1113-1121.	4.1	12
32	Psychiatry in the aftermath of COVID-19. Revista De PsiquiatrÃa Y Salud Mental, 2020, 13, 105-110.	1.8	142
33	Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use. Schizophrenia Bulletin, 2020, 46, 1547-1557.	4.3	17
34	Brief day hospital mentalization based group psychotherapy for schizophrenia spectrum disorders: A feasibility study. Actas Espanolas De Psiquiatria, 2020, 48, 64-74.	0.1	0
35	Investigación traslacional en psiquiatrÃa: el marco Research Domain Criteria (RDoC). Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 187-195.	1.8	8
36	Neuropsychiatric Symptoms as Predictors of Clinical Course in Neurodegeneration. A Longitudinal Study. Frontiers in Aging Neuroscience, 2019, 11, 176.	3.4	27

3

#	Article	IF	CITATIONS
37	Lithium: The survivor that came from the stars. Bipolar Disorders, 2019, 21, 470-471.	1.9	1
38	Sleep alterations in pediatric bipolar disorder versus attention deficit disorder. Psychiatry Research, 2019, 275, 39-45.	3.3	7
39	That which does not kill you—May afflict you? Psychological trauma in bipolar disorder. Bipolar Disorders, 2019, 21, 192-193.	1.9	2
40	A Multicenter Phase II Rater-Blinded Randomized Controlled Trial to Compare the Effectiveness of Eye Movement Desensitization Reprocessing Therapy vs. Treatment as Usual in Patients With Substance Use Disorder and History of Psychological Trauma: A Study Design and Protocol. Frontiers in Psychiatry, 2019, 10, 108.	2.6	5
41	Brain activity during traditional textbook and audiovisualâ€3D learning. Brain and Behavior, 2019, 9, e01427.	2.2	3
42	Barreras para la recuperación completa en la depresión mayor: estudio transversal multicéntrico en la práctica clÃnica. Estudio RECORD. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 141-150.	1.8	0
43	Diez años de investigación traslacional colaborativa en enfermedades mentales: el CIBERSAM. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 1-8.	1.8	68
44	Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative. International Journal of Bipolar Disorders, 2019, 7, 20.	2.2	41
45	Estudio psicométrico de la Escala de valoración de los Niveles de Atención Requerida para personas con Trastorno Mental Grave (ENAR-TMG). Revista De PsiquiatrÃa Y Salud Mental, 2018, 11, 156-168.	1.8	4
46	25 años de Eye Movement Desensitization and Reprocessing: protocolo de aplicación, hipótesis de funcionamiento y revisión sistemática de su eficacia en el trastorno por estrés postraumático. Revista De PsiquiatrÃa Y Salud Mental, 2018, 11, 101-114.	1.8	42
47	Change in functioning outcomes as a predictor of the course of depression: a 12-month longitudinal study. Quality of Life Research, 2018, 27, 2045-2056.	3.1	4
48	Indicadores de calidad en el tratamiento de pacientes con depresión, trastorno bipolar o esquizofrenia. Estudio de consenso. Revista De PsiquiatrÃa Y Salud Mental, 2018, 11, 66-75.	1.8	13
49	Cannabis Users Show Enhanced Expression of CB1-5HT2A Receptor Heteromers in Olfactory Neuroepithelium Cells. Molecular Neurobiology, 2018, 55, 6347-6361.	4.0	34
50	A 12-month study of the hikikomori syndrome of social withdrawal: Clinical characterization and different subtypes proposal. Psychiatry Research, 2018, 270, 1039-1046.	3.3	42
51	Psychometric Properties of the Spanish Version of the Panic Disorder Severity Scale. Spanish Journal of Psychology, 2018, 21, E5.	2.1	2
52	Monitorización del riesgo cardiovascular y metabólico en niños y adolescentes en tratamiento antipsicótico: un estudio descriptivo transversal. Revista De PsiquiatrÃa Y Salud Mental, 2018, 11, 19-26.	1.8	3
53	Estigma: la relevancia del contacto social en el trastorno mental. EnfermerÃa ClÃnica, 2018, 28, 111-117.	0.3	3
54	Reduced willingness to invest effort in schizophrenia with high negative symptoms regardless of reward stimulus presentation and reward value. Comprehensive Psychiatry, 2018, 87, 153-160.	3.1	8

#	Article	IF	CITATIONS
55	Looking into the effect of multi-item symptom domains on psychometric characteristics of the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16). Psychiatry Research, 2018, 267, 126-130.	3.3	4
56	Clinical features of a sample of inpatients with adjustment disorder referred to a consultation-liaison psychiatry service over 10†years. General Hospital Psychiatry, 2018, 55, 98-99.	2.4	3
57	OpenSIMPLe: A real-world implementation feasibility study of a smartphone-based psychoeducation programme for bipolar disorder. Journal of Affective Disorders, 2018, 241, 436-445.	4.1	72
58	Clinical improvement of somatic and affective symptoms in a patient with complex trauma through the use of EMDR. Report of a clinical case. Actas Espanolas De Psiquiatria, 2018, 46, 242-8.	0.1	0
59	Eye movement desensitization and reprocessing therapy versus supportive therapy in affective relapse prevention in bipolar patients with a history of trauma: study protocol for a randomized controlled trial. Trials, 2017, 18, 160.	1.6	38
60	Is a SIMPLe smartphone application capable of improving biological rhythms in bipolar disorder?. Journal of Affective Disorders, 2017, 223, 10-16.	4.1	45
61	Rationale and methods of the iFightDepression study: A double-blind, randomized controlled trial evaluating the efficacy of an internet-based self-management tool for moderate to mild depression. BMC Psychiatry, 2017, 17, 143.	2.6	9
62	EMDR beyond PTSD: A Systematic Literature Review. Frontiers in Psychology, 2017, 8, 1668.	2.1	113
63	Efficacy of Eye Movement Desensitization and Reprocessing in Children and Adolescent with Post-traumatic Stress Disorder: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Psychology, 2017, 8, 1750.	2.1	67
64	Development and assessment of an active strategy for the implementation of a collaborative care approach for depression in primary care (the INDIA·i project). BMC Health Services Research, 2017, 17, 821.	2.2	5
65	The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial. Trials, 2017, 18, 558.	1.6	32
66	Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry, 2017, 17, 250.	2.6	148
67	AN EFFECTIVE NEUROFEEDBACK TRAINING, WITH CORTISOL CORRELATES, IN A CLINICAL CASE OF ANXIETY. Universitas Psychologica, 2017, 15, .	0.6	2
68	Default Mode Network Aberrant Connectivity Associated with Neurological Soft Signs in Schizophrenia Patients and Unaffected Relatives. Frontiers in Psychiatry, 2017, 8, 298.	2.6	29
69	Comparison of treatment outcomes in severe personality disorder patients with or without substance use disorders: a 36-month prospective pragmatic follow-up study. Neuropsychiatric Disease and Treatment, 2016, 12, 1477.	2.2	6
70	NATURALISTIC COURSE OF MAJOR DEPRESSIVE DISORDER PREDICTED BY CLINICAL AND STRUCTURAL NEUROIMAGING DATA: A 5-YEAR FOLLOW-UP. Depression and Anxiety, 2016, 33, 1055-1064.	4.1	19
71	Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism. NeuroImage: Clinical, 2016, 11, 770-779.	2.7	25
72	Sluggish Cognitive Tempo in a Child and Adolescent Clinical Outpatient Setting. Journal of Psychiatric Practice, 2016, 22, 355-362.	0.7	12

#	Article	IF	Citations
73	Are there glutamate abnormalities in subjects at high risk mental state for psychosis? A review of the evidence. Schizophrenia Research, 2016, 171, 166-175.	2.0	26
74	Hospital Costs Associated With Agitation in the Acute Care Setting. Psychiatric Services, 2016, 67, 124-127.	2.0	8
75	Brief Report: Translation and Adaptation of the Theory of Mind Inventory to Spanish. Journal of Autism and Developmental Disorders, 2016, 46, 685-690.	2.7	14
76	Predictors of Relapse and Functioning in First-Episode Psychosis: A Two-Year Follow-Up Study. Psychiatric Services, 2016, 67, 227-233.	2.0	69
77	The role of hypothalamus–pituitary–adrenal genes and childhood trauma in borderline personality disorder. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 307-316.	3.2	43
78	Benefits of a Secondary Prevention Program in Suicide. Crisis, 2016, 37, 281-289.	1.2	10
79	Predicting Response Trajectories during Cognitive-Behavioural Therapy for Panic Disorder: No Association with the BDNF Gene or Childhood Maltreatment. PLoS ONE, 2016, 11, e0158224.	2.5	9
80	Association between neurological soft signs, temperament and character in patients with schizophrenia and non-psychotic relatives. PeerJ, 2016, 4, e1651.	2.0	10
81	Autolesiones no suicidas en adolescentes: revisi $ ilde{A}^3$ n de los tratamientos psicol $ ilde{A}^3$ gicos. Revista De Psicopatologia Y Psicologia Clinica, 2015, 1, .	0.2	1
82	<i>Hikikomori</i> in Spain: A descriptive study. International Journal of Social Psychiatry, 2015, 61, 475-483.	3.1	79
83	Substance Use in Patients With First-Episode Psychosis: Is Gender Relevant?. Journal of Dual Diagnosis, 2015, 11, 153-160.	1.2	19
84	Cognitive functioning after deep brain stimulation in subcallosal cingulate gyrus for treatment-resistant depression: An exploratory study. Psychiatry Research, 2015, 225, 341-346.	3.3	21
85	Resting-state functional connectivity alterations in the default network of schizophrenia patients with persistent auditory verbal hallucinations. Schizophrenia Research, 2015, 161, 261-268.	2.0	106
86	Desarrollo profesional en investigación traslacional en neurociencias y salud mental: educación y formación dentro del Centro de Investigación Biomédica en Red en Salud Mental. Revista De PsiquiatrÃa Y Salud Mental, 2015, 8, 65-74.	1.8	6
87	Conditioned Subjective Responses to Socially Relevant Stimuli in Social Anxiety Disorder and Subclinical Social Anxiety. Clinical Psychology and Psychotherapy, 2015, 22, 221-231.	2.7	14
88	Patient Management and Psychopharmacological Treatment Associated to Smoking Ban in an Acute Psychiatric Unit. Community Mental Health Journal, 2015, 51, 746-752.	2.0	4
89	Immediate cerebral metabolic changes induced by discontinuation of deep brain stimulation of subcallosal cingulate gyrus in treatment-resistant depression. Journal of Affective Disorders, 2015, 173, 159-162.	4.1	20
90	Exploring the relation between childhood trauma, temperamental traits and mindfulness in borderline personality disorder. BMC Psychiatry, 2015, 15, 180.	2.6	24

#	Article	IF	Citations
91	Relationship between cannabis and psychosis: Reasons for use and associated clinical variables. Psychiatry Research, 2015, 229, 70-74.	3.3	43
92	Home treatment in preventing hospital admission for moderate and severe mentally ill people. Psychiatry Research, 2015, 230, 709-711.	3.3	8
93	Diagnostic accuracy and adequacy of treatment of depressive and anxiety disorders: A comparison of primary care and specialized care patients. Journal of Affective Disorders, 2015, 172, 462-471.	4.1	15
94	Telephone Management Program for Patients Discharged From an Emergency Department After a Suicide Attempt. Crisis, 2015, 36, 345-352.	1.2	15
95	A randomized double-blind crossover trial of deep brain stimulation of the subcallosal cingulate gyrus in patients with treatment-resistant depression: a pilot study of relapse prevention. Journal of Psychiatry and Neuroscience, 2015, 40, 224-231.	2.4	79
96	Depression Awareness and Self-Management Through the Internet: Protocol for an Internationally Standardized Approach. JMIR Research Protocols, 2015, 4, e99.	1.0	22
97	Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment, 2014, 10, 1297.	2.2	61
98	The Spanish version of the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16): A psychometric analysis in a clinical sample. Journal of Affective Disorders, 2014, 169, 189-196.	4.1	13
99	Effects of Dialectical Behaviour Therapyâ€Mindfulness Training on Emotional Reactivity in Borderline Personality Disorder: Preliminary Results. Clinical Psychology and Psychotherapy, 2014, 21, 363-370.	2.7	39
100	Psychometric properties of the Spanish self-report version of the Panic Disorder Severity Scale. Comprehensive Psychiatry, 2014, 55, 1467-1472.	3.1	15
101	Exploring the interaction between childhood maltreatment and temperamental traits on the severity of borderline personality disorder. Comprehensive Psychiatry, 2014, 55, 311-318.	3.1	51
102	Propiedades psicométricas de la versión española de la Philadelphia Mindfulness Scale. Revista De PsiquiatrÃa Y Salud Mental, 2014, 7, 157-165.	1.8	18
103	Pharmacological and clinical dilemmas of prescribing in coâ€morbid adult attentionâ€deficit/hyperactivity disorder and addiction. British Journal of Clinical Pharmacology, 2014, 77, 337-356.	2.4	24
104	Individual residual symptoms and functional impairment in patients with depression. Psychiatry Research, 2014, 220, 258-262.	3.3	18
105	Spanish Medical Students' Attitudes and Views towards Mental Health and Psychiatry: a Multicentric Cross-Sectional Study. Academic Psychiatry, 2014, 38, 332-338.	0.9	11
106	Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case–control sample from Spain. Schizophrenia Research, 2014, 159, 107-113.	2.0	36
107	Association between methylation of the glucocorticoid receptor gene, childhood maltreatment, and clinical severity in borderline personality disorder. Journal of Psychiatric Research, 2014, 57, 34-40.	3.1	105
108	Validation of the Spanish version of the borderline symptom list, short form (BSL-23). BMC Psychiatry, 2013, 13, 139.	2.6	49

#	Article	IF	Citations
109	Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate. BMC Psychiatry, 2013, 13, 71.	2.6	15
110	Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis. BMC Psychiatry, 2013, 13, 51.	2.6	62
111	Emotional responses to a negative emotion induction procedure in Borderline Personality Disorder. International Journal of Clinical and Health Psychology, 2013, 13, 9-17.	5.1	14
112	Differences in attention and impulsivity between borderline personality disorder and bipolar disorder. Psychiatry Research, 2013, 210, 1307-1309.	3.3	21
113	Effectiveness of a telephone management programme for patients discharged from an emergency department after a suicide attempt: Controlled study in a Spanish population. Journal of Affective Disorders, 2013, 147, 269-276.	4.1	78
114	A psychometric analysis of the Clinically Useful Depression Outcome Scale (CUDOS) in Spanish patients. Journal of Affective Disorders, 2013, 151, 920-923.	4.1	8
115	Hippocampal abnormalities of glutamate/glutamine, N-acetylaspartate and choline in patients with depression are related to past illness burden. Journal of Psychiatry and Neuroscience, 2013, 38, 107-116.	2.4	73
116	Direct Experience and the Course of Eating Disorders in Patients on Partial Hospitalization: A Pilot Study. European Eating Disorders Review, 2013, 21, 399-404.	4.1	5
117	Effects of illness duration and treatment resistance on grey matter abnormalities in majordepression. British Journal of Psychiatry, 2013, 202, 434-440.	2.8	72
118	Toward a Genuinely Patient-Centered Metric of Depression Recovery. JAMA Psychiatry, 2013, 70, 1375.	11.0	4
119	Satisfaction With Methadone as a Medication. Journal of Clinical Psychopharmacology, 2012, 32, 69-74.	1.4	17
120	Early Switch Strategy in Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2012, 32, 479-486.	1.4	29
121	A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology, 2012, 15, 589-600.	2.1	181
122	Deep brain stimulation of the subcallosal cingulate gyrus: further evidence in treatment-resistant major depression. International Journal of Neuropsychopharmacology, 2012, 15, 121-133.	2.1	170
123	Update on Deep Brain Stimulation for Treatment-Resistant Depression. Current Psychiatry Reviews, 2012, 8, 175-182.	0.9	0
124	Physiological and self-assessed emotional responses to emotion-eliciting films in borderline personality disorder. Psychiatry Research, 2012, 200, 437-443.	3.3	40
125	One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. Psychiatry Research, 2012, 200, 693-701.	3.3	29
126	Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: A double-blind randomized study. Journal of Affective Disorders, 2012, 143, 47-55.	4.1	18

#	Article	IF	CITATIONS
127	Farmacogenética de las reacciones adversas a los antipsicóticos en pacientes con esquizofrenia. Psiquiatria Biologica, 2012, 19, 15-20.	0.1	0
128	Effects of the dialectical behavioral therapy-mindfulness module on attention in patients with borderline personality disorder. Behaviour Research and Therapy, 2012, 50, 150-157.	3.1	76
129	The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: lodine-123-iodobenzamide single photon emission computed tomography study. Psychiatry Research - Neuroimaging, 2012, 201, 73-77.	1.8	14
130	Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: An in vivo SPECT study. Schizophrenia Research, 2011, 129, 169-171.	2.0	13
131	Axis II comorbidity in borderline personality disorder is influenced by sex, age, and clinical severity. Comprehensive Psychiatry, 2011, 52, 725-730.	3.1	41
132	Optimal cutoff point of the Hamilton Rating Scale for Depression according to normal levels of social and occupational functioning. Psychiatry Research, 2011, 186, 133-137.	3.3	51
133	Density of striatal D2 receptors in untreated first-episode psychosis: An I123-IBZM SPECT study. European Neuropsychopharmacology, 2011, 21, 861-866.	0.7	17
134	Ventromedial prefrontal spectroscopic abnormalities over the course of depression: A comparison among first episode, remitted recurrent and chronic patients. Journal of Psychiatric Research, 2011, 45, 427-434.	3.1	115
135	Can We Really Accelerate and Enhance the Selective Serotonin Reuptake Inhibitor Antidepressant Effect?. Journal of Clinical Psychiatry, 2011, 72, 962-969.	2.2	53
136	Dr Portella and Colleagues Reply. Journal of Clinical Psychiatry, 2011, 72, 1558.	2.2	0
137	A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. International Clinical Psychopharmacology, 2010, 25, 349-355.	1.7	41
138	A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes. Journal of Affective Disorders, 2010, 120, 221-225.	4.1	80
139	Quetiapine in the treatment of refractory irritable bowel syndrome. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 715-716.	4.8	5
140	Predictors of schizophrenia in patients with a first episode of psychosis. Psychiatry Research, 2010, 175, 11-14.	3.3	12
141	Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Research, 2010, 176, 109-113.	3.3	359
142	Reduced platelet G protein-coupled receptor kinase 2 in major depressive disorder: Antidepressant treatment-induced upregulation of GRK2 protein discriminates between responder and non-responder patients. European Neuropsychopharmacology, 2010, 20, 721-730.	0.7	28
143	Differential Association of Circadian Genes with Mood Disorders: CRY1 and NPAS2 are Associated with Unipolar Major Depression and CLOCK and VIP with Bipolar Disorder. Neuropsychopharmacology, 2010, 35, 1279-1289.	5.4	310
144	Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: A 3-month randomised controlled clinical trial. Behaviour Research and Therapy, 2009, 47, 353-358.	3.1	194

#	Article	IF	CITATIONS
145	Neural correlates of impaired emotional discrimination in borderline personality disorder: An fMRI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1537-1545.	4.8	61
146	Depressive Relapse After Initial Response to Subcallosal Cingulate Gyrus-Deep Brain Stimulation in a Patient with a Treatment-Resistant Depression: Electroconvulsive Therapy as a Feasible Strategy. Biological Psychiatry, 2009, 66, e11-e12.	1.3	19
147	Pindolol augmentation enhances response outcomes in first depressive episodes. European Neuropsychopharmacology, 2009, 19, 516-519.	0.7	24
148	Stages of change in dialectical behaviour therapy for borderline personality disorder. British Journal of Clinical Psychology, 2008, 47, 417-426.	3.5	32
149	Failure to detect an association between the serotonin transporter gene and borderline personality disorder. Journal of Psychiatric Research, 2008, 42, 87-88.	3.1	30
150	Abnormal P300 in people with high risk of developing psychosis. NeuroImage, 2008, 41, 553-560.	4.2	87
151	Clinical characteristics of agitated psychotic patients treated with an oral antipsychotics attended in the emergency room setting: NATURA study. International Journal of Psychiatry in Clinical Practice, 2008, 12, 127-133.	2.4	2
152	A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. International Clinical Psychopharmacology, 2008, 23, 138-149.	1.7	11
153	Ziprasidone in the Treatment of Borderline Personality Disorder. Journal of Clinical Psychiatry, 2008, 69, 603-608.	2.2	59
154	Hospitalization and Pharmacotherapy for Borderline Personality Disorder in a Psychiatric Emergency Service. Psychiatric Services, 2007, 58, 1199-1204.	2.0	32
155	Cost-Effectiveness Analysis of Ziprasidone versus Haloperidol in??Sequential Intramuscular/Oral Treatment of Exacerbation of Schizophrenia. Clinical Drug Investigation, 2007, 27, 633-645.	2.2	3
156	Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. NeuroImage, 2006, 29, 662-666.	4.2	38
157	Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. European Psychiatry, 2006, 21, 11-20.	0.2	52
158	Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatric Genetics, 2006, 16, 25-29.	1.1	51
159	Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. Psychopharmacology, 2006, 189, 145-153.	3.1	43
160	Behavioural Inhibition and Behavioural Activation Systems in current and recovered major depression participants. Personality and Individual Differences, 2006, 40, 215-226.	2.9	90
161	Dopamine D2 receptor occupancy by risperidone: Implications for the timing and magnitude of clinical response. Psychiatry Research - Neuroimaging, 2006, 148, 175-183.	1.8	19
162	Double-Blind, Placebo-Controlled Study of Dialectical Behavior Therapy Plus Olanzapine for Borderline Personality Disorder. American Journal of Psychiatry, 2005, 162, 1221-1224.	7.2	186

#	Article	IF	CITATIONS
163	Is grey literature essential for a better control of publication bias in psychiatry? An example from three meta-analyses of schizophrenia. European Psychiatry, 2005, 20, 550-553.	0.2	46
164	Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 91-96.	4.8	19
165	Regulation of Platelet α2A-Adrenoceptors, Gi Proteins and Receptor Kinases in Major Depression: Effects of Mirtazapine Treatment. Neuropsychopharmacology, 2004, 29, 580-588.	5.4	44
166	Ziprasidone in the Acute Treatment of Borderline Personality Disorder in Psychiatric Emergency Services. Journal of Clinical Psychiatry, 2004, 65, 1281-1283.	2.2	24
167	Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 767-770.	4.8	12
168	Repetitive transcranial magnetic stimulation for the treatment of depression. British Journal of Psychiatry, 2003, 182, 480-491.	2.8	279
169	SPECT mapping of cerebral activity changes induced by repetitive transcranial magnetic stimulation in depressed patients. A pilot study. Psychiatry Research - Neuroimaging, 2001, 106, 151-160.	1.8	70
170	Augmentation of Fluoxetine's Antidepressant Action by Pindolol: Analysis of Clinical, Pharmacokinetic, and Methodologic Factors. Journal of Clinical Psychopharmacology, 2001, 21, 36-45.	1.4	60
171	Fluoxetine in the Prevention of Depressive Recurrences: A Double-Blind Study. Journal of Clinical Psychopharmacology, 2001, 21, 417-424.	1.4	52
172	Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Biological Psychiatry, 1999, 46, 518-524.	1.3	37
173	A Double-blind, Randomized, Placebo-Controlled Trial of Pindolol Augmentation in Depressive Patients Resistant to Serotonin Reuptake Inhibitors. Archives of General Psychiatry, 1999, 56, 375.	12.3	146
174	Relationship Between Blood Serotonergic Variables, Melancholic Traits, and Response to Antidepressant Treatments. Journal of Clinical Psychopharmacology, 1998, 18, 222-230.	1.4	31
175	Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet, The, 1997, 349, 1594-1597.	13.7	304
176	Retention in a low-threshold methadone maintenance program. Drug and Alcohol Dependence, 1996, 41, 55-59.	3.2	68
177	Solvent fluctuations in electron transfer processes. Journal of Molecular Liquids, 1995, 63, 77-88.	4.9	1
178	On the validity of marcus relationship for dissociative electron transfer reactions in solution. Journal of Molecular Liquids, 1994, 60, 147-160.	4.9	2
179	A Monte Carlo Simulation of the Electrochemical Reduction of Alkyl Halides in Water. On the Validity of Marcus' Relationship. Journal of the American Chemical Society, 1994, 116, 10117-10123.	13.7	15
180	Monte Carlo simulation of the diabatic free energy curves for a dissociative electron transfer reaction in a polar solvent. Journal of Computational Chemistry, 1992, 13, 1057-1065.	3.3	11

ARTICLE IF CITATIONS

181 Clinics., 0, , 51-110. 0